September 2026 FDA Recall Ranolazine by Ajanta Pharma Usa Inc
D-0010-2027 - Failed Dissolution Specifications

This Class II drug recall was voluntarily initiated by Ajanta Pharma Usa Inc on September 17, 2026 for the product Ranolazine. The FDA reported the reason for recall as failed dissolution specifications. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0010-2027

Reason for Recall
Failed Dissolution Specifications: below specification
Initiated
09-17-2026
Reported
10-07-2026
Quantity

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Ajanta Pharma USA Inc
Nationwide in the US.
Ranolazine Extended-Release Tablets, 1000 mg, 60-count bottle, Rx Only, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807. NDC: 27241-126-02

Batch or Lot Expiration Information

Lot# Lot: DJ25134, Exp 11/30/2028